Onkologie. 2024:18(3):213-215 | DOI: 10.36290/xon.2024.040
Combination therapy in advanced primary metastatic hormone-sensitive prostate cancer
- Onkologická klinika, 2. LF UK a FN Motol, Praha
The treatment for metastatic hormone-sensitive prostate cancer has undergone numerous changes in recent years, thus offering patients a number of new options. In 2022, two randomized phase III trials, PEACE-1 and ARASENS, demonstrated the efficacy of early intensification therapy wherein the triplet combination therapy of androgen deprivation therapy (ADT), ARTA (abiraterone - PEACE-1, darolutamide - ARASENS), and docetaxel showed improved overall survival (OS) compared with double therapy (androgen deprivation therapy + docetaxel). The present case report demonstrates a successful use of triplet therapy in a patient with advanced primary metastatic prostate cancer with carcinomatosis of the bone marrow.
Keywords: metastatic hormone-sensitive prostate cancer, triplet, docetaxel, abiraterone, bone marrow carcinomatosis.
Accepted: June 18, 2024; Published: June 24, 2024 Show citation
References
- Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399:1695-1707. doi: 10.1016/S0140-6736(22)00367-1.
Go to original source... 
Go to PubMed... - Mittal A, Sridhar SS, Ong M, et al. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care. Curr Oncol. 2023;30(4):4365-4378. doi: 10.3390/curroncol3004033. Go to original source...
- Smith MR, Hussain M, Saad F. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132-1142. doi: 10.1056/NEJMoa2119115. Go to original source... Go to PubMed...
- Hussain M, Tombal B, Saad F, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16. PMID: 36795843. Go to original source... Go to PubMed...
- Riaz IB, Naqvi SAA, He H, et al. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol. 2023:e227762. doi: 10.1001/jamaoncol.2022.7762. Go to original source... Go to PubMed...
- ESMO 2022: Effect of Abiraterone-Prednisone in mCSPC with Neuroendocrine and Very High-Risk Features in the PEACE-1 Trial. [(accessed on 23 December 2022)]. Available from: https://www.urotoday.com/conference-highlights/esmo-2022/esmo-2022-prostate-cancer/139407-esmo-2022-effect-of-abiraterone-prednisone-in-mcspc-with-neuroendocrine-and-very-high-risk-features-in-the-peace-1-trial.html.
- Saoud R, Heidar NA, Cimadamore A, et al. Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer. Cells. 2020;9(9). doi: 10.3390/cells9092116. Go to original source... Go to PubMed...
- Shahait M, Abu-Hijlih R, Salamat A, et al. Bone marrow involvement in patients with metastatic castration sensitive prostate cancer. PLoS One. 2022;17:e0270956. Go to original source... Go to PubMed...